Drug intelligence / Profile preview

modified-DC vaccine

Development stage: Unknown
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous, Intradermal, Intranodal, Intratumoral, Intramuscular

Overview

The modified-DC vaccine is a novel autologous dendritic cell (DC) vaccine designed for patients with resected non-small cell lung cancer (NSCLC). This vaccine is engineered by pulsing dendritic cells with tumor-associated antigens survivin and MUC1, silencing suppressor of cytokine signaling 1 (SOCS1) to enhance DC activation, and stimulating them with flagellin to further boost immune responses. The goal is to induce a robust anti-tumor immune response, prevent recurrence, and improve patient quality of life. Early clinical data suggest it is well-tolerated and shows modest antitumor activity.

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on modified-DC vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on modified-DC vaccine.

Explore the full profile